Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Should AMTL be defined as a distinct diagnostic entity?

Jonathan Bond • 18 Jun 2020
ESH AL 2020
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia Rare Diseases T-Cell Prolymphocytic Leukemia

Jonathan Bond, MB BCh BAO, MRCPI, FRCPath, PhD, University College Dublin, Dublin, Ireland, discusses recent proposals to define acute myeloid/T-lymphoblastic leukemia (AMTL) as a distinct diagnostic entity. Prof. Bond reveals that the transcriptional overlap in interface acute leukemias provides support for the proposed classification of AMTL as a separate entity. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jonathan Bond

12:51
Acute leukemias at the T-lymphoid/myeloid interface
Jonathan Bond • 18 Jun 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals